Patents by Inventor Walter Strapps

Walter Strapps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for TTR gene editing and treating ATTR amyloidosis
    Patent number: 11965165
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: April 23, 2024
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent
    Publication number: 20240124897
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: July 31, 2023
    Publication date: April 18, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Yong Chang, Seth C. Alexander, Kristy M. Wood, Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • METHODS FOR TREATING INFLAMMATORY OCULAR DISEASES WITH COMPLEMENT FACTOR H
    Publication number: 20240024416
    Abstract: The present disclosure relates to dosage regimens of complement factor H (CFH) protein for treating patients having inflammatory ocular diseases or conditions (e.g., age-related macular degeneration or early-onset macular dystrophies). The present disclosure also provides methods of treating patients having inflammatory ocular diseases, disorders, or conditions (e.g., age-related macular degeneration) using complement factor H (CFH) based on the levels of certain protein biomarkers, such as complement components and inflammation markers, in ocular samples of the patients.
    Type: Application
    Filed: October 29, 2021
    Publication date: January 25, 2024
    Inventors: Suresh Katti, Scott Lauder, Robyn Biggs, Walter Strapps, Lenore von Krusenstiern
  • Compositions and methods for TTR gene editing and treating ATTR amyloidosis
    Patent number: 11795460
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: October 24, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Modified Guide RNAs
    Publication number: 20230287400
    Abstract: This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Application
    Filed: September 1, 2022
    Publication date: September 14, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Amy Madison Rhoden Smith, David V. Morrissey, Walter Strapps
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis
    Publication number: 20230257747
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: August 17, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods for Treating Alpha-1 Antitrypsin Deficiency
    Publication number: 20230212575
    Abstract: Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of ?1-antitrypsin (AAT), such as seen in subjects having ?1-antitrypsin deficiency (AATD), are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: July 6, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Walter Strapps, Reynald Michael Lescarbeau
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis
    Publication number: 20230118592
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: December 9, 2022
    Publication date: April 20, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent
    Publication number: 20230044994
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: September 27, 2021
    Publication date: February 9, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Yong Chang, Seth C. Alexander, Kristy M. Wood, Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use Thereof
    Publication number: 20230035659
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene in combination with administration of a corticosteroid are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), in which a guide RNA and a corticosteroid are administered, are provided.
    Type: Application
    Filed: September 27, 2021
    Publication date: February 2, 2023
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Yong CHANG, Seth C. ALEXANDER, Kristy M. WOOD, Arti Mahendra Prakash KANJOLIA, Shobu ODATE, Jessica Lynn SEITZER, Reynald Michael LESCARBEAU, Walter STRAPPS
  • Compositions and methods for treating alpha-1 antitrypsin deficiency
    Patent number: 11549107
    Abstract: Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of ?1-antitrypsin (AAT), such as seen in subjects having ?1-antitrypsin deficiency (AATD), are provided.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: January 10, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Walter Strapps, Reynald Michael Lescarbeau
  • METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH CFH-ENCODING VECTORS
    Publication number: 20220396807
    Abstract: The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more mutations in complement factor H (CFH), complement component 3 (C3), and complement factor B (CFB) by administering to the patients a recombinant adeno-associated virus (rAAV) vector encoding a CFH polypeptide or biologically active fragment and/or variant thereof.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 15, 2022
    Inventors: James McLaughlin, Lisa Huang, Suresh Katti, Walter Strapps, Melissa Deck
  • Modified guide RNAs
    Patent number: 11479767
    Abstract: This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 25, 2022
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Amy Madison Rhoden Smith, David V. Morrissey, Walter Strapps
  • Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing
    Publication number: 20210222173
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the LDHA gene are provided. Compositions and methods for treating subjects having hyperoxaluria are provided.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 22, 2021
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Zachary William Dymek, Shobu Odate, Anette Huebner, Srijani Sridhar, Bradley Andrew Murray, Walter Strapps
  • Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)
    Publication number: 20210163943
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the HAO1 gene are provided. Compositions and methods for treating subjects having primary hyperoxaluria type 1 (PH1), are provided.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Zachary William Dymek, Shobu Odate, Bradley Andrew Murray, Reynald Michael Lescarbeau, Anette Huebner, Walter Strapps, Sarah Beth Hesse
  • ANTISENSE-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
    Publication number: 20200325481
    Abstract: The present disclosure provides compositions and methods for treating, preventing, or inhibiting diseases of the eye. In one aspect, the disclosure provides HTRA1 ASO agents and methods of using the same.
    Type: Application
    Filed: November 15, 2019
    Publication date: October 15, 2020
    Inventors: Walter Strapps, James McLaughlin
  • CRISPR-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
    Publication number: 20200291427
    Abstract: The present disclosure provides compositions and methods for treating, preventing, or inhibiting diseases of the eye. In one aspect, the disclosure provides compositions comprising HTRA1 guide RNA sequences and uses thereof.
    Type: Application
    Filed: November 15, 2019
    Publication date: September 17, 2020
    Inventors: Walter Strapps, James McLaughlin
  • RNAi-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
    Publication number: 20200270614
    Abstract: The present disclosure provides compositions and methods for treating, preventing, or inhibiting diseases of the eye. In one aspect, the disclosure provides HTRA1 RNAi agents and methods of using the same.
    Type: Application
    Filed: November 15, 2019
    Publication date: August 27, 2020
    Inventors: Walter Strapps, James McLaughlin
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis
    Publication number: 20200248180
    Abstract: Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.
    Type: Application
    Filed: March 24, 2020
    Publication date: August 6, 2020
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Arti Mahendra Prakash Kanjolia, Shobu Odate, Jessica Lynn Seitzer, Reynald Michael Lescarbeau, Walter Strapps
  • Modified Guide RNAs
    Publication number: 20190316121
    Abstract: This disclosure relates to modified single and dual guide RNAs having improved in vitro and in vivo activity in gene editing methods.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Amy Madison Rhoden Smith, David V. Morrissey, Walter Strapps